je.st
news
Tag: eisai
Eisai sells RTP facility to Biogen; results in 35 layoffs
2015-07-16 21:57:53| Biotech - Topix.net
Eisai employs 180 workers in RTP and the move will result in 35 layoffs. Another 100 workers will be eligible for jobs with Biogen and Eisai will retain 45 employees, according to the companies.
Tags: results
facility
sells
layoffs
Eisai Co's (ESALY) CEO Haruo Naito on Q4 2015 Results - Earnings Call Transcript
2015-05-14 18:41:42| Logistics - Topix.net
Before we begin, I would like to ask you to confirm whether the materials are all in front of you. There is presentation slide and press report and reference materials and ASCO abstract list that was released to the press today and epilepsy related press release.
Eisai to Present New Research on Oncology Products and Pipeline at 51st ASCO Annual Meeting
2015-05-14 14:35:07| Logistics - Topix.net
Highlights Include New Clinical Data on Halaven in Soft Tissue Sarcoma and on Lenvima in Renal Cell Carcinoma TOKYO, May 14, 2015 - - Eisai Co., Ltd. announced today that a series of abstracts highlighting new study results on Halaven and Lenvima with a novel binding mode, "lenvatinib") will be presented during the 51st Annual Meeting of the American Society of Clinical Oncology , taking place in Chicago, the United States, from May 29 to June 2, 2015.
Tags: products
research
present
meeting
Japan's Eisai to cut about 450 jobs in U.S.
2015-04-10 01:34:11| Biotech - Topix.net
Japanese pharmaceutical company Eisai Co Ltd said it would cut about 25 percent, or about 450 jobs, in the United States as part of a realignment to create a more efficient and focused company. The company's U.S. unit Eisai Inc employs about 1,800 people in the United States, according to its website, across operations such as research and development, manufacturing, sales and administration.
Eisai and Merck Enter Collaboration to Explore Novel Combination Regimens of Anti-PD-1 Therapy with Multi-targeting RTK Inhibitor and Microtubule Dynamics Inhibitor in Multiple Types of Cancer
2015-03-05 00:30:00| Merck.com - Product News
Dateline City: TOKYO & KENILWORTH, N.J. Combination clinical studies of lenvatinib, eribulin and pembrolizumab to be explored TOKYO & KENILWORTH, N.J.--(BUSINESS WIRE)--Eisai Co., Ltd. and Merck (NYSE:MRK), known as MSD outside the U.S. and Canada, through a subsidiary, announced today a clinical trial collaboration to evaluate the safety, tolerability and efficacy of Mercks anti-PD-1 therapy, pembrolizumab (marketed in the U.S. under the brand name KEYTRUDA), in combination with Eisai oncology compounds lenvatinib mesylate (a multi-targeting RTK inhibitor marketed in the U.S. Language: English Contact: Eisai Public Relations Department+81-(0)3-3817-5120orEisai Investor Relations+81-(0)3-3817-5327orMerck Media RelationsPamela Eisele, 267-305-3558or Claire Mulhearn, 908-236-1118orMerck Investor RelationsJustin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more